Investors

“We believe that Resverlogix provides investors with a tremendous investment opportunity as our novel technology platform is very well positioned in the largest therapeutic market in the world.”
A. Brad Cann, CFO

Why Invest In Resverlogix CVD Technology?

  1. Atherosclerosis is the major underlying cause of CVD, which represents a large commercial market
  2. ApoA-I is a clinically validated target for the treatment and prevention of atherosclerosis
  3. NexVas PR technology (small molecules to increase ApoA-I) is uniquely positioned in the competitive landscape of therapies to treat CVD
  4. NexVas PR represents an unprecedented opportunity for future alliance partners
  5. Resverlogix’s senior management team have extensive business and scientific acumen

Market Opportunity

Our CVD programs, NexVas™ PR, NexVas™ VI and ReVas™, are focused on developing innovative solutions that address atherosclerosis and other emerging targets in cardiovascular disease. There are approximately 350 million patients that require treatment for atherosclerosis. Our lead drug candidate RVX-208 represents a potential breakthrough for CVD patients. We have a world lead in developing small molecules that enhance the transcription of ApoA-I and ApoA1 is a clinically validated target for reducing CVD risk. We are dedicated to moving our technologies toward clinical development and successful commercialization. This represents an unprecedented market opportunity for Resverlogix with an optimistic outcome for patients suffering with CVD.